Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…Abstract Number: 468 • 2014 ACR/ARHP Annual Meeting
Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients
Background/Purpose Despite efficacy of anti-tumor necrosis factors (anti-TNFs) in treating chronic immune conditions, some patients (pts) report serious adverse events (SAEs) highlighting a need to…Abstract Number: 71 • 2014 ACR/ARHP Annual Meeting
Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank
Background/Purpose: Very large epidemiological studies designed to investigate genetic and environmental influences on disease, known as ‘biobanks' can be used to look at associations between…Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting
Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome
Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study
Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases
Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »